Potentiation of temozolomide activity against glioblastoma cells by aromatase inhibitor letrozole

被引：0
|
作者：
Aniruddha S. Karve
Janki M. Desai
Nimita Dave
Trisha M. Wise-Draper
Gary A. Gudelsky
Timothy N. Phoenix
Biplab DasGupta
Soma Sengupta
David R. Plas
Pankaj B. Desai
机构：
[1] University of Cincinnati,Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy
[2] University of Cincinnati College of Medicine,Division of Hematology/Oncology
[3] Cincinnati Children’s Hospital,Division of Oncology
[4] University of Cincinnati College of Medicine,Department of Neurology and Rehabilitation Medicine
[5] University of Cincinnati College of Medicine,Department of Cancer Biology
[6] Nimbus Therapeutics,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2022年 / 90卷
关键词：
Glioblastoma; Temozolomide; Drug-resistance; Aromatase inhibitors; Letrozole; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：345 / 356
页数：11
相关论文
共 50 条
  • [41] Role of the aromatase inhibitor letrozole in the management of uterine leiomyomas in premenopausal women
    Duhan, Nirmala
    Madaan, Shikha
    Sen, Jyotsna
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2013, 171 (02) : 329 - 332
  • [42] Identification of the aromatase inhibitor letrozole in urine by gas chromatography/mass spectrometry
    Mareck, U
    Sigmund, G
    Opfermann, G
    Geyer, H
    Thevis, M
    Schänzer, W
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2005, 19 (24) : 3689 - 3693
  • [43] Cancer and immune cells evolutionary trajectories under treatment with the aromatase inhibitor letrozole and the CDK4/6 inhibitor ribociclib
    Fongard, Marie
    Schmiester, Leonard
    Ghannoum, Salim
    Bjornstad, Marius
    Bosnjak, Tatjana
    Kleivbo, Signe
    Selsas, Knut
    Geisler, Stephanie
    Fjermeros, Kamilla
    Bhargava, Sameer
    Seyedzadeh, Manouchehr
    Buvarp, Unn-Cathrin
    Vuoriluoto, Aino
    Nam Thi Nguyen
    Luders, Torben
    Lambrechts, Diether
    Lyngra, Marianne
    Frigessi, Arnoldo
    Kristensen, Vessela
    Geisler, Jurgen
    Tekpli, Xavier
    CANCER RESEARCH, 2024, 84 (09)
  • [44] Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor
    Colussi, DM
    Parisot, CY
    Lefèvre, GY
    JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (08): : 727 - 735
  • [45] Effect of aromatase inhibitor letrozole on the proliferation of spermatogonia by regulating the MAPK pathway
    Wang, Shunde
    Wang, Shuhong
    Li, Hang
    Li, Xiaoxia
    Xie, Menglin
    Wen, Jiayu
    Li, Meicai
    Long, Tengbo
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2018, 15 (06) : 5269 - 5274
  • [46] The individual or combinational effects of Hesperetin and Letrozole on the activity and expression of aromatase in MCF-7 cells
    Rahideh, S. T.
    Shidfar, F.
    Nourbakhsh, M.
    Hoseini, M.
    Koohdani, F.
    Entezam, M.
    Keramatipour, M.
    CELLULAR AND MOLECULAR BIOLOGY, 2016, 62 (06) : 38 - 43
  • [47] Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide
    Gerlach, Samantha L.
    Dunlop, Rachael A.
    Metcalf, James S.
    Banack, Sandra A.
    Cox, Paul Alan
    JOURNAL OF NATURAL PRODUCTS, 2022, 85 (01): : 34 - 46
  • [48] The aromatase inactivator exemestane suppresses serum leptin levels significantly in vivo - in contrast to the aromatase inhibitor letrozole
    Bahrami, N.
    Jabeen, S.
    Sauer, T.
    Kristensen, V. N.
    Gundersen, J. M.
    Geisler, J.
    ANNALS OF ONCOLOGY, 2019, 30 : 35 - 35
  • [49] Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole
    Jelovac, D
    Sabnis, G
    Long, BJ
    Macedo, L
    Goloubeva, OG
    Brodie, AMH
    CANCER RESEARCH, 2005, 65 (12) : 5380 - 5389
  • [50] Synergistic Effects of Resveratrol and Temozolomide Against Glioblastoma Cells: Underlying Mechanism and Therapeutic Implications
    Liu, Yusi
    Song, Xue
    Wu, Moli
    Wu, Jiao
    Liu, Jia
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8341 - 8354
12345